BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PCI-32765: Interim Phase Ib/II data

Interim data from 61 patients in the open-label, U.S. Phase Ib/II PCYC-1102-CA trial showed that once-daily 420 and 840 mg oral PCI-32765 produced ORRs of 67% and 68% at a median follow-up of 12.6 and 9.3 months, respectively. Additionally, the estimated 12-month...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >